An Asn to Lys polymorphism in the third intracellular loop of the human α2A-adrenergic receptor imparts enhanced agonist-promoted Gi coupling

被引:59
作者
Small, KM
Forbes, SL
Brown, KM
Liggett, SB
机构
[1] Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA
[2] Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45267 USA
关键词
D O I
10.1074/jbc.M004550200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
alpha (2A)-Adrenergic receptors (alpha (2A)AR) are presynaptic autoinhibitory receptors of noradrenergic neurons in the central and peripheral sympathetic nervous systems, which act to dynamically regulate neurotransmitter release. Signaling through the G(i)/G(o) family of G-proteins, the receptor subserves numerous homeostatic and central nervous system functions. A single nucleotide polymorphism of this receptor, which results in an Asn to Lys substitution at amino acid 251 of the third intracellular loop, was identified in the human population. The frequency of Lys-251 was 10-fold greater in African-Americans than in Caucasians, but was not associated with essential hypertension. To determine the consequences of this substitution, wild-type and Lys-251 receptors were expressed in CHO and COS-7 cells. Expression, ligand binding, and basal receptor function were unaffected by the substitution. However, agonist-promoted [S-35]GTP gammaS binding was similar to 40% greater with the Lys-251 receptor. This enhanced agonist function was observed with catecholamines, azepines, and imidazolines albeit to different degrees. In studies of agonist-promoted functional coupling to G(i), the polymorphic receptor displayed enhanced inhibition of adenylyl cyclase (60 +/- 4.4 versus 46 +/- 4.1% inhibition) and markedly enhanced stimulation of MAP kinase (57 +/- versus 15- +/- a-fold increase over basal) compared with wild-type alpha (2A)AR. The potency of epinephrine in stimulating inositol phosphate accumulation was increased similar to4 fold with the Lys-251 receptor. Unlike previously described variants of G-protein-coupled receptors, where the minor species causes either a loss of function or increased non-agonist function, Lys-251 alpha (2A)AR represents a new class of polymorphism whose phenotype is a gain of agonist-promoted function.
引用
收藏
页码:38518 / 38523
页数:6
相关论文
共 34 条
[1]   Abnormal regulation of the sympathetic nervous system in α2A-adrenergic receptor knockout mice [J].
Altman, JD ;
Trendelenburg, AU ;
Macmillan, L ;
Bernstein, D ;
Limbird, L ;
Starke, K ;
Kobilka, BK ;
Hein, L .
MOLECULAR PHARMACOLOGY, 1999, 56 (01) :154-161
[2]   Expression of altered α2-adrenergic phenotypic traits in normotensive humans at genetic risk of hereditary (essential) hypertension [J].
Dao, TT ;
Kailasam, MT ;
Parmer, RJ ;
Le, HV ;
Le Verge, R ;
Kennedy, BP ;
Ziegler, MG ;
Insel, PA ;
Wright, FA ;
O'Connor, DT .
JOURNAL OF HYPERTENSION, 1998, 16 (06) :779-792
[3]   HIGH-LEVEL TRANSIENT GENE-EXPRESSION IN HUMAN LYMPHOID-CELLS BY SV40 LARGE T-ANTIGEN BOOST [J].
DECHASSEVAL, R ;
DEVILLARTAY, JP .
NUCLEIC ACIDS RESEARCH, 1992, 20 (02) :245-250
[4]   4 CONSECUTIVE SERINES IN THE 3RD INTRACELLULAR LOOP ARE THE SITES FOR BETA-ADRENERGIC-RECEPTOR KINASE-MEDIATED PHOSPHORYLATION AND DESENSITIZATION OF THE ALPHA(2A)-ADRENERGIC RECEPTOR [J].
EASON, MG ;
MOREIRA, SP ;
LIGGETT, SB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (09) :4681-4688
[5]   THE PALMITOYLATED CYSTEINE OF THE CYTOPLASMIC TAIL OF ALPHA(2A)-ADRENERGIC RECEPTORS CONFERS SUBTYPE-SPECIFIC AGONIST-PROMOTED DOWN-REGULATION [J].
EASON, MG ;
JACINTO, MT ;
THEISS, CT ;
LIGGETT, SB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (23) :11178-11182
[6]  
EASON MG, 1992, J BIOL CHEM, V267, P25473
[7]   Chimeric mutagenesis of putative G-protein coupling domains of the alpha(2A)-adrenergic receptor - Localization of two redundant and fully competent G(1) coupling domains [J].
Eason, MG ;
Liggett, SB .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (22) :12826-12832
[8]   Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins [J].
Exton, JH .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1996, 36 :481-509
[9]  
GOLDSTEIN DS, 1991, HYPERTENSION S3, V18, P40
[10]  
GREEN SA, 1993, J BIOL CHEM, V268, P23116